Emmaus Life Sciences Debt 2024

Emmaus Life Sciences Aktienanalyse

What does Emmaus Life Sciences do?

Emmaus Life Sciences Inc. is an innovative US-American company that develops, produces, and markets medications based on L-Glutamine. The company was founded in 2000 by Dr. Yutaka Niihara, a Japanese researcher who grew up in the USA and received his doctorate from Harvard Medical School. The idea for founding Emmaus Life Sciences arose from the observation of patients with sickle cell anemia, an inherited blood disease. These patients suffer from intense pain attacks caused by the clumping of red blood cells in the body. Dr. Niihara and his colleagues researched the effects of L-Glutamine on these pain attacks and were able to demonstrate that L-Glutamine can significantly reduce the frequency and intensity of the pain attacks. Based on these research results, Emmaus Life Sciences developed the medication "Endari," which was approved by the US-American regulatory authority FDA in 2017. "Endari" is the first medication specifically approved for the treatment of sickle cell anemia. It is intended to reduce the frequency and severity of pain attacks in patients with sickle cell anemia. Since its founding in 2000, Emmaus Life Sciences has expanded significantly. The company now has multiple locations in the USA and employs over 150 employees. Emmaus Life Sciences operates in two business areas: medications and health products. In the medication area, Emmaus Life Sciences focuses on the development of drugs for rare diseases. In addition to "Endari," the company is working on the development of medications for the treatment of mucopolysaccharidosis (MPS) and acid peptidase deficiency (ASM). In the health products area, Emmaus Life Sciences specializes in the production and marketing of dietary supplements. The company has developed a range of products based on L-Glutamine as the active ingredient. These products are intended to support the health of athletes, people with special dietary needs, older adults, and people with certain diseases. Emmaus Life Sciences' products include L-Glutamine powder for daily use, L-Glutamine capsules for athletes and bodybuilders, L-Glutamine for clinical nutrition, and a special L-Glutamine product for people with chronic kidney disease. Emmaus Life Sciences is an innovative company that builds its products on scientifically validated research results. The company specializes in the development of medications and health products that help people improve their health and increase their quality of life. Emmaus Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Emmaus Life Sciences's Debt Structure

Emmaus Life Sciences's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Emmaus Life Sciences's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Emmaus Life Sciences’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Emmaus Life Sciences’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Emmaus Life Sciences stock

What is the debt of Emmaus Life Sciences this year?

Emmaus Life Sciences has a debt level of 27.85 USD this year.

What was the debt of Emmaus Life Sciences compared to the previous year?

The debt of Emmaus Life Sciences has increased by -3.27% compared to the previous year dropped.

What are the consequences of high debt for investors in Emmaus Life Sciences?

High debt can pose a risk for investors of Emmaus Life Sciences, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Emmaus Life Sciences?

Low debt means that Emmaus Life Sciences has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Emmaus Life Sciences affect the company?

An increase in debt of Emmaus Life Sciences can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Emmaus Life Sciences affect the company?

A reduction in debt of Emmaus Life Sciences can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Emmaus Life Sciences?

Some factors that can influence the debt of Emmaus Life Sciences include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Emmaus Life Sciences so important for investors?

The debts of Emmaus Life Sciences are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Emmaus Life Sciences take to change the debt?

To change the debt, Emmaus Life Sciences can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Emmaus Life Sciences pay?

Over the past 12 months, Emmaus Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emmaus Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Emmaus Life Sciences?

The current dividend yield of Emmaus Life Sciences is .

When does Emmaus Life Sciences pay dividends?

Emmaus Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Emmaus Life Sciences?

Emmaus Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Emmaus Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Emmaus Life Sciences located?

Emmaus Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Emmaus Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Emmaus Life Sciences from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Emmaus Life Sciences pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Emmaus Life Sciences in the year 2023?

In the year 2023, Emmaus Life Sciences distributed 0 USD as dividends.

In which currency does Emmaus Life Sciences pay out the dividend?

The dividends of Emmaus Life Sciences are distributed in USD.